Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.
[Iovance Biotherapeutics, Inc.]